HER2-Positive Breast Cancer | Clinical

Olaparib Improves Disease–Free Survival in Early HER2-Negative Breast Cancer

July 20, 2021

Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.

Wuerstein Discusses the Implications of the KAMILLA Trial and T-DM1 in HER2+ Metastatic Breast Cancer

July 14, 2021

In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.

HER2+ Status at Diagnosis in Patients With mBC Shows More Favorable PFS Than HER2-Negative Status

July 12, 2021

A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.

KAMILLA Trial Shows Practice-Changing Safety/Efficacy for HER2+ mBC

June 24, 2021

Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.